BioCardia Inc (BCDA) Options

BCDA new 52=week low

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

BCDA under $3

BCDA under $3

Understand and agree. They get little to no traction on the market. Although, most important imo is they do get traction with the largest health insurer in the country putting millions into BCDA's trials. Bizarre to me that few are paying attention to such a large indication as I'm sure you are aware with them being in such a late stage of their trials. Small burn and only need a small amount of capital to get to the Phase 3 readout. They already have 90% of the Phase 3 BCDA01 data, so I guess we will see what happens with the final data set.

Yes. Have a personal interest as I have heart disease.

Have traded it sporadically.

Disappointed that don’t ever seem to get much traction with this therapy even with good data.

Murocman

Been tracking this company for years. Anyone else?

BCDA new 52 week low

$BCDA catalysts;
''Our planned Morph-DNA submission to the FDA for approval of a product family from 5 French to 8 French diameters is on track for submission in the second quarter of 2024''
''Q2: Enrollment in the CardiAMP Cell Therapy Heart Failure Trial''
''Q2: Completion of low dose cohort''
''Q2: Third revenue sharing partnership agreement''

BCDA new 52 week low

BCDA new 52 week low

Watching news .. 08:17 AM EDT, 06/07/2024 (MT Newswires) -- BioCardia (BCDA) said Friday that the US Patent Office has granted a patent for the company's radial and transendocardial biotherapeutic delivery catheter through 2036.

The Helix biotherapeutic delivery system is being evaluated in ongoing clinical trials, according to BioCardia. It relates to medical procedures and systems for substance delivery to the heart through a radial artery and for the intracardiac delivery of cellular aggregates and other materials, the company said.

BioCardia's stock climbed more than 44% in recent Friday premarket activity.

Price: 6.3000, Change: +1.93, Percent Change: +44.16

Keep watching.........

Let's get a rise back up

Easy money

Grabbed 1.20

Got 1.28’s now to push it

Tapping it up

Already past Pluto now heading for the next solar system

1.94 in the works

great

https://dilutiontracker.com/app/search/BCDA

$BCDA NEWS https://finviz.com/quote.ashx?t=BCDA&p=d

https://dilutiontracker.com/app/search/BCDA

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the Food and Drug Administration (FDA) approval of its Phase III clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.

BioCardia announces that the Food and Drug Administration (FDA) has approved its proposed CardiAMP Heart Failure II study protocol. The currently ongoing CardiAMP Heart Failure trial has completed enrollment and it is anticipated that the final data analyses will be reported in Q4 2024. In an interim analysis of available data to date for study patients followed up through two years, those having N-terminal pro B-type natriuretic peptide (NT-proBNP) levels consistent as demarcating heart failure (>500 pg/ml) at screening-baseline showed meaningful clinical improvements over controls, including a 59% relative risk reduction in heart death and a 54% relative risk reduction of Major Adverse Cardiovascular or Cerebrovascular events (MACCE). Further, all clinical outcome measures evaluated at follow-up for this interim subset favored cell therapy over guideline directed medical therapy, including having improved quality-of-life as measured using the Minnesota Living with Heart Failure Questionnaire, reduced NT-proBNP levels, greater walk distance as measured using the 6-minute walk distance test, and improved cardiac measures such as left ventricular ejection fraction and left ventricular end systolic and end diastolic volumes. Statistical significance (p

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

Let’s do this

BCDA new 52 week low

BCDA new 52 week low

BCDA new 52 week low

BCDA new 52 week low

BCDA new 52 week low

Bad news out .62 watch for the dump today

BCDA new 52 week low

BCDA new 52 week low

BCDA new 52 week low

BCDA new 52 week low

Shady day in Sunnyvale.

Nice open

Grabbed some $2.86

Time for another leg up!

https://finance.yahoo.com/news/biocardia-announces-fda-approval-ind-111500114.html

Looking good

News

Going to be retesting highs here during power hour or after hours

$3.70 nice :)

Looking good here

$4.85 next leg up :)

* * $BCDA Video Chart 12-15-2020 * *

Link to Video - click here to watch the technical chart video

They anticipate .. not definitive

Phase 3 DSMB feedback due December 17th